Noradrenergic control of the synthesis of two rat pineal proteins.
Pineal physiology is controlled by norepinephrine released from sympathetic nerves terminating in the gland. In the present study, the effect of norepinephrine on the labelling of specific proteins was investigated by incubating glands with [35S]methionine and then resolving the proteins by two-dimensional polyacrylamide gel electrophoresis; the patterns were analyzed by computer-assisted image analysis. The most prominent effects of norepinephrine were distinct and consistent increases in the labelling of two proteins (37 kDa, pI = 6.0, 50 kDa, pI = 6.0), designated adrenergically induced protein (AIP 37/6 and AIP 50/6). In both cases, norepinephrine was effective at low concentrations (EC50 = 10 nM). Pharmacological studies indicated that the effects of norepinephrine on both proteins involved a beta-adrenergic receptor, and that cyclic AMP was the second messenger. Pulse-chase labelling experiments revealed that these effects of norepinephrine did not involve post-translational modification of previously labelled precursor proteins, but depended upon de novo synthesis of protein. An inhibitor of mRNA synthesis, actinomycin-D, was found to block the effect of norepinephrine on AIP 50/6 but not on AIP 37/6, suggesting that norepinephrine acted on AIP 50/6 via a transcriptional mechanism and on AIP 37/6 via a translational mechanism. These in vitro studies were extended into in vivo investigations by measuring silver-stained AIP 37/6 in the two-dimensional gels. Changes in the amount of AIP 37/6 in pineal glands were studied in response to treatments which block the adrenergic stimulation of the gland, including exposure to constant lighting or removal of the superior cervical ganglia. Both treatments reduced AIP 37/6 by 50-75% in 8 weeks. These observations, together with those from in vitro studies, suggest that the amount of AIP 37/6 in the pineal gland is regulated by norepinephrine; and further, that norepinephrine acts through a beta-adrenergic-cyclic AMP mechanism to control AIP 37/6 synthesis at a translational level.
Voisin
P
P
Section of Neuroendocrinology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892.
Harrington
M G
MG
Weller
J L
JL
Goldman
D
D
Merril
C R
CR
Klein
D C
DC
D000320:Adrenergic Fibers / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D000242:Cyclic AMP / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D008970:Molecular Weight; D009419:Nerve Tissue Proteins / Q000096:biosynthesis*; D009638:Norepinephrine / Q000502:physiology*; D010870:Pineal Gland / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D013562:Sympathectomy; D014158:Transcription, Genetic
D009419:Nerve Tissue Proteins; D003609:Dactinomycin; D000242:Cyclic AMP; D009638:Norepinephrine